-
1Academic Journal
Πηγή: Российские биомедицинские исследования, Vol 10, Iss 1 (2025)
Θεματικοί όροι: аллерген-специфическая иммунотерапия (АСИТ), поллиноз, Medicine (General), R5-920, сублингвальная иммунотерапия (СЛИТ), эозинофильный эзофагит (ЭоЭ)
Σύνδεσμος πρόσβασης: https://doaj.org/article/ad32fa224cfe45349846f12e7985c2b3
-
2Academic Journal
Συγγραφείς: Anna A. Kosova, Anastasiya V. Fayans, Aishan Е. Ibaduiiaeva, Kirill S. Gusev, Anastaiya N. Nikovaeva, Dayana G. Bayburdyan, Dmitriy V. Kaiinin, Eieonora Yu. Ivanova, Marina I. Korniiova, Saak G. Serobyan, Irina R. Fomina, Ziki Sh. Bukhsaev, А. А. Косова, А. В. Фаянс, A. Э. Ибадуллаева, К. С. Гусев, А. Н. Николаева, Д. Г. Байбурдян, Д. В. Калинин, Э. Ю. Иванова, М. И. Корнилова, С. Г. Серобян, И. Р. Фомина, З. Ш. Бухсаев
Πηγή: Pediatric pharmacology; Том 21, № 6 (2024); 520-533 ; Педиатрическая фармакология; Том 21, № 6 (2024); 520-533 ; 2500-3089 ; 1727-5776
Θεματικοί όροι: дети, bronchial asthma, atopic dermatitis, eosinophilic esophagitis, children, бронхиальная астма, атопический дерматит, эозинофильный эзофагит
Περιγραφή αρχείου: application/pdf
Relation: https://www.pedpharma.ru/jour/article/view/2554/1656; Коннов П.Е., Арсеньева А.А. Эффективность и безопасность применения первого таргетного биологического препарата дупилумаб в терапии тяжелого непрерывно-рецидивиру-ющего атопического дерматита // Вестник дерматологии и венерологии. — 2023. — Т. 99. — № 1. — С. 62-70. — https://doi.org/10.25208/vdvl384; Чурюкина Э.В. Дупилумаб: аспекты применения при тяжелой бронхиальной астме в реальной клинической практике // Практическая пульмонология. — 2022. — № 2. — С. 3-10. — https://doi.org/10.24412/2409-6636-2022-12937; Глухова E.A., Кувшинова Е.Д., Ревякина B.A. Опыт применения дупилумаба у пациентов с тяжелым атопическим дерматитом//Аллергология и иммунология в педиатрии. — 2022. — № 3. — С. 14-23. — https://doi.org/10.53529/2500-1175-2022-3-14-23; Drugs@FDA: FDA-Approved Drugs, in: U.S. Food & Drug Administration. Available online: https://www.accessdata.fda.gov/scripts/cder/daf. Accessed on November 08, 2024.; Augustin M, Bauer A, Ertner K, et al. Dupiiumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatol Ther (Heidelb). 2023;13(3):803-816. https://doi.org/10.1007/sl3555-023-00894-3; SilverbergJI, BarbarotS, Gadkari A, etal. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. https://doi.org/10.1016/J.anai.2020.12.020; Потекаев FI.Fl., Серов Д.НІ., Михайлова И.А. и др. Современные аспекты патогенеза и терапии атопического дерматита // Клиническая дерматология и венерология. — 2019. — Т. 18. — № 3. — С. 259-263. — https://doi.org/10.17116/klinderma201918031259; Paller AS, Weidinger S, Capozza K, et al. Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey). Dermatol Ther (Heidelb). 2023;13(4):961-980. https://doi.org/10.1007/sl3555-022-00850-7; Flarb FI, Chatila TA. Mechanisms of Dupiiumab. Clin Exp Allergy. 2020;50(1):5-14. https://doi.org/10.llll/cea.13491; Flamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupiiumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J A/Zergy CTin Immunol. 2014;134(6):1293-1300. https://doi.org/10.1016/J.Jaci.2014.10.013; Wang A, Zhou Y, Luo Y, et al. Fligh loading-dose of dupiiumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https://doi.org/10.3389/fimmu.2023.1160710; BlauveltA, Guttman-YasskyE, Paller AS, etal. Long-Term Efficacy and Safety of Dupiiumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365-383. https://doi.org/10.1007/s40257-022-00683-2; Ferrucci S, Casazza G, Zussino M, et al. Predictive Factors of Early Response to Dupiiumab in Patients with Moderate-to-Severe Atopic Dermatitis. J Clin Med. 2023;12(20):6575. https://doi.org/10.3390/Jcml2206575; Kim EJ, Hlobik M, Ho T. Effectiveness of dupiiumab in pediatric patients with a nummular phenotype of atopic dermatitis. Pediatr Dermatol. 2024;41(3):455-457. https://doi.org/10.llll/pde.15541; Kim JW, Kim M, Ahn GS, Na Jl. Dupilumabprovidesrapid improvement for morphologic variants of paediatric atopic dermatitis: A case series. Indian J Dermatol Venereol Leprol. 2022;88(6):834-839. https://doi.org/10.25259/IJDVL_759_2021; Gelato F, Mastorino L, Stepkina E, et al. Is Dupiiumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? J Clin Med. 2023;12(6):2189. https://doi.org/10.3390/Jcml2062189; Мурашкин H.H., Опрятин Л.А., Павлова E.C. и др. Эффективность и безопасность дупилумаба при тяжелом атопическом дерматите у детей в возрасте до 6 лет: два клинических случая // Вопросы современной педиатрии. — 2023. — Т. 22. — № 5. — С. 443-449. — https://doi.org/10.15690/vsp.v22i5.2622; Kamphuis E, BoesJes CM, Loman L, et al. Dupiiumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Pediatr Allergy Immunol. 2022;33(12):el3887. https://doi.org/10.1111/pai.l3887; Paller AS, Simpson EL, Siegfried EC, et al. Dupiiumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919. https://doi.org/10.1016/S0140-6736(22)01539-2; Paller AS, Siegfried EC, Thaęi D, et al. Efficacy and safety of dupiiumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293. https://doi.0rg/lO.lOl6/J.Jaad.2020.06.054; Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupiiumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(l):44-56. DOI:10.1001/Jamaderma-tol.2019.3336; Siegfried EC, Simpson EL, Cork MJ, et al. Dupiiumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatol Ther (Heidelb). 2023;13(9):1987-2000. https://doi.org/10.1007/sl3555-023-00960-w; Paller AS, Bansal A, Simpson EL, et al. Clinically Meaningful Responsesto Dupiiumab In Adolescentswith Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119-131. https://doi.org/10.1007/s40257-019-00478-y; Cork MJ, Lockshin B, Pinter A, et al. Clinically Meaningful Responses to Dupiiumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. Acta Derm Venereol. 2024;104:advl3467. https://doi.org/10.2340/actadv.vl04.13467; Siegfried EC, Cork MJ, Katoh N, et al. Dupiiumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial. Am J Clin Dermatol. 2023;24(5):787-798. https://doi.org/10.1007/s40257-023-00791-7; Siegfried EC, Bieber T, Simpson EL, et al. Effect of Dupiiumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021;22(2):243-255. https://doi.org/10.1007/s40257-020-00583-3; Paller AS, Wollenberg A, Siegfried E, et al. Laboratory Safety of Dupiiumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatr Drugs. 2021;23(5):515-527. https://doi.org/10.1007/s40272-021-00459-x; Paller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. https://doi.org/10.1007/s40272-022-00553-8; Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. https://doi.org/10.1111/bjd.19460; Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. https://doi.org/10.1007/s40257-024-00859-y; Global Burden of Disease due to Asthma. In: The Global Asthma Report 2022. Available online: http://www.globalas-thmareport.org/burden/burden.php. Accessed on November 08, 2024.; Бяловский Ю.Ю., Глотов С.И., Ракитина И.С., Ермачкова А.Н. Патогенетические аспекты фенотипирования бронхиальной астмы // Российский медико-биологический вестник имени академика И.П. Павлова. — 2024. — Т. 32. — № 1. — С. 145–158. — https://doi.org/10.17816/PAVL0VJ181606; Ricciardolo FLM, Bertolini F, Carriero V. The Role of Dupilumab in Severe Asthma. Biomedicines. 2021;9(9):1096. https://doi.org/10.3390/biomedicines9091096; Maison N, Omony J, Illi S, et al. T2-high asthma phenotypes across lifespan. Eur Respir J. 2022;60(3):2102288. https://doi.org/10.1183/13993003.02288-2021; Игнатова Г.Л., Антонов В.Н., Макарова Е.А., Кочеткова С.А. Опыт использования дупилумаба в лечении тяжелой бронхиальной астмы // Терапевтический архив. — 2020. — Т. 92. — № 8. — С. 95–99. — https://doi.org/10.26442/00403660.2020.08.000718; Tajiri T, Suzuki M, Nishiyama H, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study. Allergol Int. 2024;73(3):406–415. https://doi.org/10.1016/j.alit.2024.02.002; Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children (Basel). 2022;9(8):1253. https://doi.org/10.3390/children9081253; Scott G, Asrat S, Allinne J, et al. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091. https://doi.org/10.1016/j.cyto.2022.156091; Pelaia C, Pelaia G, Crimi C, et al. Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines (Basel). 2022;10(6):974. https://doi.org/10.3390/vaccines10060974; Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496. https://doi.org/10.1056/ NEJMoa1804092; Jackson DJ, Bacharier LB, Phipatanakul W, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023;131(1):44–51.e4. https://doi.org/10.1016/j.anai.2023.03.014; Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-toSevere Asthma. J Allergy Clin Immunol Pract. 2023;11(4):1213– 1220.e2. https://doi.org/10.1016/j.jaip.2022.11.043; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению // Пульмонология. — 2022. — Т. 32. — № 3. —С. 393–447. — https://doi.org/10.18093/0869-01892022-32-3-393-447; Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003; Rajvanshi N, Kumar P, Goyal JP. Global Initiative for Asthma Guidelines 2024: An Update. Indian Pediatr. 2024;61(8):781–786.; Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093; Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021;385(24):2230–2240. https://doi.org/10.1056/NEJMoa2106567; Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. https://doi.org/10.1016/S22132600(21)00322-2; Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. https://doi.org/10.1016/j.jaip.2019.08.050; Bourdin A, Papi AA, Corren J, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76(1):269–280. https://doi.org/10.1111/all.14611; Rabe KF, Pavord ID, Castro M, et al. Dupilumab efficacy and safety in patients with asthma and blood eosinophils 500 cells·μL-1. Eur Respir J. 2022;59(6):2102577. https://doi.org/10.1183/13993003.02577-2021; Bleecker ER, Panettieri RA Jr, Lugogo NL, et al. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils. J Immunol Res. 2023;2023:9943584. https://doi.org/10.1155/2023/9943584; Bacharier LB, Guilbert TW, Katelaris CH, et al. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. J Allergy Clin Immunol Pract. 2024;12(4):948–959. https://doi.org/10.1016/j.jaip.2023.12.006; Papadopoulos NG, Szefler SJ, Bacharier LB, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157– 2167. https://doi.org/10.1111/all.15743; Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;62(5):2300558. https://doi.org/10.1183/13993003.00558-2023; Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36(6):1410-6. https://doi.org/10.1183/09031936.00117509; Lu MA, Eckmann T, Ruvalcaba E, et al. Family management of asthma in Head Start preschool children. Ann Allergy Asthma Immunol. 2022;128(2):178–183. https://doi.org/10.1016/j.anai.2021.11.002; Bacharier LB, Maspero JF, Katelaris CH, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024;12(1):45–54. https://doi.org/10.1016/S2213-2600(23)00303-X; Manti S, Giallongo A, Pecora G, et al. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study. Pediatr Pulmonol. 2023;58(4):1085–1091. https://doi.org/10.1002/ppul.26298; Бурлуцкая А.В., Статова А.В., Долбнева О.В. и др. Эозинофильный эзофагит у детей: клинические случаи // Кубанский научный медицинский вестник. — 2022. — Т. 29. — № 4.— С. 94–106.— https://doi.org/10.25207/1608-6228-2022-29-4-94-106 [Burlutskaya AV, Statova AV, Dolbneva OV, et al. Eosinophilic Esophagitis in Children: Clinical Cases. Kuban Scientific Medical Bulletin. 2022;29(4):94–106. (In Russ). https://doi.org/10.25207/1608-6228-2022-29-4-94-106]; Votto M, De Filippo M, Caimmi S, et al. A Practical Update on Pediatric Eosinophilic Esophagitis. Children (Basel). 2023;10(10):1620. https://doi.org/10.3390/children10101620; Menard-Katcher C, Furuta GT, Kramer RE. Dilation of Pediatric Eosinophilic Esophagitis: Adverse Events and Short-term Outcomes. J Pediatr Gastroenterol Nutr. 2017;64(5):701–706. https://doi.org/10.1097/MPG.0000000000001336; Dowling PJ, Neuhaus H, Polk BI. The Role of the Environment in Eosinophilic Esophagitis. Clin Rev Allergy Immunol. 2019;57(3):330– 339. https://doi.org/10.1007/s12016-018-8697-9; Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(5):416–423. https://doi.org/10.1016/j.anai.2020.03.020; Bawany F, Franco AI, Beck LA. Dupilumab: One therapy to treat multiple atopic diseases. JAAD Case Rep. 2020;6(11):1150–1152. https://doi.org/10.1016/j.jdcr.2020.08.036; Syverson EP, Rubinstein E. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. JPGN Rep. 2022;3(2):e180. https://doi.org/10.1097/PG9.0000000000000180; Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589– 593. https://doi.org/10.1016/j.anai.2022.01.019; Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990–1004. https://doi.org/10.1016/S2468-1253(23)00204-2; Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. https://doi.org/10.1056/NEJMoa2205982; Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. https://doi.org/10.1056/NEJMoa2312282; McCann E, Chehade M, Spergel JM, et al. Validation of the novel Eosinophilic Esophagitis Impact Questionnaire. J Patient Rep Outcomes. 2023;7(1):120. https://doi.org/10.1186/s41687-023-00654-z; Nguyen N, Burger C, Skirka S, et al. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023;77(4):536–539. https://doi.org/10.1097/MPG.0000000000003901; Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab. ACG Case Rep J. 2022;9(11):e00887. https://doi.org/10.14309/crj.0000000000000887; Lee CJ, Dellon ES. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2024;22(2):252–258. https://doi.org/10.1016/j.cgh.2023.08.015; https://www.pedpharma.ru/jour/article/view/2554
-
3Academic Journal
Συγγραφείς: Niankovskyi, S.L., Horodylovska, M.I., Ivantsiv, V.A., Boiko, O.I.
Πηγή: Zdorovʹe Rebenka, Vol 10, Iss 2.1.62.1, Pp 107-110 (2015)
CHILD`S HEALTH; № 2.1.62.1 (2015); 107-110
Здоровье ребенка-Zdorovʹe rebenka; № 2.1.62.1 (2015); 107-110
Здоров'я дитини-Zdorovʹe rebenka; № 2.1.62.1 (2015); 107-110Θεματικοί όροι: eosinophilic esophagitis, діти, еозинофільний езофагіт, гастроінтестинальна харчова алергія, children, gastrointestinal food allergy, дети, эозинофильный эзофагит, гастроинтестинальная пищевая аллергия, Pediatrics, RJ1-570, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: https://doaj.org/article/60ce249d156e47fb9a61ef06e23c4477
http://childshealth.zaslavsky.com.ua/article/download/83438/127524
https://paperity.org/p/241232302/eosinophilic-esophagitis-as-one-of-the-manifestations-of-gastrointestinal-food-allergy-in
http://childshealth.zaslavsky.com.ua/article/view/83438 -
4Academic Journal
Συγγραφείς: V.I. Averin, K.Y. Marakhouski, SI «Republican Scientific, Y.A. Kaminskaya
Πηγή: Хірургія дитячого віку, Vol 0, Iss 2(67), Pp 55-58 (2020)
PAEDIATRIC SURGERY. UKRAINE; № 2(67) (2020): Paediatric Surgery. Ukraine; 55-58
ХИРУРГИЯ ДЕТСКОГО ВОЗРАСТА; № 2(67) (2020): Хирургия детского возраста; 55-58
Хірургія дитячого віку; № 2(67) (2020): Хірургія дитячого віку; 55-58Θεματικοί όροι: RD1-811, eosinophilic esophagitis, children, esophageal disease, еозинофільний езофагіт, діти, хвороба стравоходу, Surgery, эозинофильный эзофагит, дети, болезнь пищевода, Pediatrics, RJ1-570, 3. Good health
Περιγραφή αρχείου: application/pdf
-
5Academic Journal
Συγγραφείς: Kataeva, A. D., Omelkova, D. M., Kupriyanova, I. N., Naumova, V. V., Bozrov, R. M., Катаева, А. Д., Омелькова, Д. М., Куприянова, И. Н., Наумова, В. В., Бозров, Р. М.
Πηγή: Сборник статей
Θεματικοί όροι: EOSINOPHILIC ESOPHAGITIS, ESOPHAGEAL EOSINOPHILIA, PROTON PUMP INHIBITORS, TOPICAL GLUCOCORTICOSTEROIDS, ЭОЗИНОФИЛЬНЫЙ ЭЗОФАГИТ, ЭОЗИНОФИЛИЯ ПИЩЕВОДА, ИНГИБИТОРЫ ПРОТОННОЙ ПОМПЫ, ТОПИЧЕСКИЕ ГЛЮКОКОРТИКОСТЕРОИДЫ
Περιγραφή αρχείου: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/13467
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/13467
-
6Academic Journal
Συγγραφείς: A. V. Ishbuldina, R. F. Rakhmaeva, A. A. Kamalova, D. V. Usova, A. M. Khazieva, A. M. Nigmatullina, M. Sh. Zainetdinova, А. В. Ишбулдина, Р. Ф. Рахмаева, А. А. Камалова, Д. В. Усова, А. М. Хазиева, А. М. Нигматуллина, М. Ш. Зайнетдинова
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 68, № 5 (2023); 89-94 ; Российский вестник перинатологии и педиатрии; Том 68, № 5 (2023); 89-94 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: диетотерапия, glycogen storage disease, IXa glycogenosis, eosinophilic esophagitis, Legg–Calvé–Perthes disease, diet correction, болезни накопления гликогена, гликогеноз IXа типа, эозинофильный эзофагит, болезнь Легга– Кальве–Пертеса
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1881/1420; Zembura M., Matusik Р. Sarcopenic Obesity in Children and Adolescents: A Systematic Review. Frontiers in endocrinology 2022; 13:914740. DOI:10.3389/fendo.2022.914740; Donini L.M., Busetto L., Bischoff S. C., Cederholm T., Ballesteros-Pomar M.D., Batsis J.A. et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obesity Facts 2022; 15(3): 321–335. DOI:10.1159/000521241; Polyzos S.A., Margioris A.N. Sarcopenic obesity. Hormones (Athens) 2018; 17(3): 321–331. DOI:10.1007/ s42000–018–0049-x; Koliaki C., Liatis S., Dalamaga M., Kokkinos A. Sarco-penic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives. Cur Obes Report. 2019; 8(4): 458–471. DOI:10.1007/s13679–019–00359–9; Клинические рекомендации: Гликогеновая болезнь у детей. https://www.pediatrussia.ru/news/Гликогеновая%20болезнь_на_сайт_спр.pdf. / Ссылка активна на 22.04.2023.; Клинические рекомендации Министерства здравоохранения РФ Эозинофильный эзофагит. 2022; 64. https://rnmot.org/images/public/uploads/RNMOT/Docs/Клин_рекомендации_Эоз%20_11_12_2022.pdf / Ссылка активна на 27.07.2023 г.; Крутикова Н.Ю., Виноградова А.Г. Болезнь Легга–Кальве–Пертеса. Вопросы современной педиатрии 2015; 14(5): 548–552. DOI:10.15690/vsp.v14i5.1437; Российская ассоциация эндокринологов. Клинические рекомендации: ожирение у детей. 2021; 70. https://cr.minzdrav.gov.ru/schema/229_2. / Ссылка активна на 27.07.2023 г.; Методические рекомендации MP 2.3.1.0253–21 “Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации” https://www.garant.ru/products/ipo/prime/doc/402716140. Ссылка активная на 27.07.2023 г; Болотова Н.В., Аверьянов А.П., Филина Н.Ю., Захарова Е.Ю., Меликян М.А., Великоцкая О.А. и др. Гликогеноз IX типа у ребенка 9 лет. Проблемы эндокринологии 2017; 63(2): 139–142. DOI:10.14341/probl2017632139–142
-
7Academic Journal
Συγγραφείς: R. F. Khakimova, A. A. Kamalova, Yu. M. Akhmatova, D. E. Tarasova, N. S. Poliakov, A. R. Khabibullina, A. G. Kuznetsova, Р. Ф. Хакимова, А. А. Камалова, Ю. М. Ахматова, Д. Э. Тарасова, Н. С. Поляков, А. Р. Хабибуллина, А. Г. Кузнецова
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 68, № 5 (2023); 126-130 ; Российский вестник перинатологии и педиатрии; Том 68, № 5 (2023); 126-130 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: лечение, eosinophilic esophagitis, relapse, treatment, эозинофильный эзофагит, рецидив
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1886/1425; Эозинофильный эзофагит. Клинические рекомендации Министерства здравоохранения РФ 2022 года; 64 с. https://www.rnmot.ru/public/uploads/RNMOT/clinical/2022/Клин_рекомендации_Эоз%20_11_12_2022.pdf / Ссылка активна на 03.08.2023.; Хакимова Р.Ф., Камалова А.А., Поляков Н.С., Хомяков А.Е., Низамова Р.А., Зайнетдинова М.Ш., Чеминава Л.Д. Эозинофильный эзофагит у детей: опыт диагностики и клинического наблюдения в условиях многопрофильной больницы. Российский аллергологический журнал 2023; 20(1): 97–103. DOI:10.36691/RJA2085; Yousef E., Korotkaya Y., Simpson A.B. Eosinophilic esophagitis in children: Updates and practical aspects of management for allergists in a non-tertiary care private practice setup. Allergy Asthma Proc 2022; 43(1): 5–11. DOI:10.2500/aap.2022.43.210084; Cavalli E., Brusaferro A., Pieri E.S., Cozzali R., Farinelli E., De’ Angelis G.L., Esposito S. Eosinophilic esophagitis in children: doubts and future perspectives. J Transl Med 2019; 17(1): 262. DOI:10.1186/s12967–019–2014–0; Barni S., Arasi S., Mastrorilli C., Pecoraro L., Giovannini M., Moriet F. et al. Pediatric eosinophilic esophagitis: a review for the clinician. Ital J Pediatr 2021; 47: 230. DOI:10.1186/S13052–021–01178–2; Dellon E.S., Liacouras C.A., Molina-Infante J., Furuta G.T., Spergel J.M., Zevit N. et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology 2018; 155(4): 1022–1033.e10. DOI:10.1053/j.gastro.2018.07.009; Будкина Т.Н., Садиков И.С., Макарова С.Г., Лохматов М.М., Суржик А.В., Ерешко О.А. Эозинофильный эзофагит у детей. Вопросы современной педиатрии 2016; 15(3): 239–249. DOI:10.15690/vsp.v15i3.1560; Lucendo A.J., Molina-Infante J., Arias Á., von Arnim U., Bredenoord A.J., Bussmann C. et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J 2017; 5(3): 335–358. DOI:10.1177/2050640616689525; Налетов А.В., Вьюниченко Ю.С., Масюта Д.И. Родительская комплаентность и влияющие на нее факторы при лечении детей с синдромом раздраженного кишечника. Педиатр 2018; 9(2): 67–70. DOI:10.17816/PED9267–70
-
8Academic Journal
Συγγραφείς: Руслан Абдуллаевич Насыров, Юрий Павлович Успенский, Юлия Александровна Фоминых, Елена Юрьевна Калинина, Александр Александрович Гнутов
Πηγή: University Therapeutic Journal, Vol 4, Iss 3 (2022)
Θεματικοί όροι: морфологические особенности пищевода, лимфоцитарный эзофагит, эозинофильный эзофагит, IgG4-ассоциированный эзофагит, Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/4119; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920
Σύνδεσμος πρόσβασης: https://doaj.org/article/9e1b64c5060945e1bb887a9a567fb820
-
9Academic Journal
Πηγή: University Therapeutic Journal, Vol 4, Iss 3 (2022)
Θεματικοί όροι: IgG4-ассоциированный эзофагит, эозинофильный эзофагит, морфологические особенности пищевода, Medicine, лимфоцитарный эзофагит
Σύνδεσμος πρόσβασης: https://doaj.org/article/9e1b64c5060945e1bb887a9a567fb820
-
10Academic Journal
Συγγραφείς: Albina Nikolaevna Davydova, Natalya Fedorovna Shaposhnikova, Vadim Vladislavovich Markelov, Olesya Alekseevna Yurchenko
Πηγή: Siberian Journal of Life Sciences and Agriculture, Vol 12, Iss 2, Pp 73-83 (2020)
Θεματικοί όροι: пищевая аллергия, аллергодерматоз, хроническая крапивница, эозинофильный эзофагит, Agriculture, Science
Περιγραφή αρχείου: electronic resource
Relation: http://journal-s.org/index.php/vmno/article/view/12723; https://doaj.org/toc/2658-6649; https://doaj.org/toc/2658-6657
Σύνδεσμος πρόσβασης: https://doaj.org/article/194f7d7f37cd456e9f15427634df5006
-
11Academic Journal
Συγγραφείς: Юрий Павлович Успенский, Елена Юрьевна Калинина
Πηγή: University Therapeutic Journal, Vol 4, Iss 3 (2022)
Θεματικοί όροι: морфологические особенности пищевода, лимфоцитарный эзофагит, эозинофильный эзофагит, IgG4-ассоциированный эзофагит, Medicine
Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/4119; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920; https://doaj.org/article/9e1b64c5060945e1bb887a9a567fb820
Διαθεσιμότητα: https://doaj.org/article/9e1b64c5060945e1bb887a9a567fb820
-
12Academic Journal
Συγγραφείς: Gubergrits, N. B., Mouzyka, S. V.
Πηγή: Современная гастроэнтерология; № 5 (2018); 100-115
Сучасна гастроентерологія; № 5 (2018); 100-115
Modern Gastroenterology; № 5 (2018); 100-115Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, эозинофильный эзофагит, дисфагия, вклинение пищи, макроамилаземия, дифференциальная диагностика, топические кортикостероиды, ингибиторы протонной помпы, элиминационная диета, еозинофільний езофагіт, дисфагія, вклинення їжі, макроамілаземія, диференційна діагностика, топічні кортикостероїди, інгібітори протонної помпи, елімінаційна дієта, eosinophilic esophagitis, dysphagia, food impaction, macroamylasemia, differential diagnostics, topical steroids, proton pump inhibitors, elimination diet, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://sgastro.com.ua/article/view/147528
-
13Academic Journal
Συγγραφείς: O. M. Kurbacheva3, M. E. Dyneva, N. I. Ilina, О. М. Курбачева, М. Е. Дынева, Н. И. Ильина
Πηγή: Meditsinskiy sovet = Medical Council; № 16 (2021); 186-196 ; Медицинский Совет; № 16 (2021); 186-196 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: биологическая терапия, Il-13, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, eosinophilic esophagitis, eosinophilic pneumonia, dupilumab, biological therapy, ИЛ-13, атопический дерматит, бронхиальная астма, полипозный риносинусит, пруриго, эозинофильный эзофагит, эозинофильная пневмония, дупилумаб
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6477/5867; Ильина Н.И., Курбачева О.М. Моноклональные антитела в системе противоастматического лечения. Российский аллергологический журнал. 2018;15(3):5–15. https://doi.org/10.36691/RJA145.; Corren J. New targeted therapies for uncontrolled asthma. J Allergy Clin Immunol Pract. 2019;7(5):1394–1403. https://doi.org/10.1016/j.jaip.2019.03.022.; Diamont Z., Dahlen S.-E. Type 2 inflammation and the evolving profile of uncontrolled persistent asthma. Eur Med J. 2018;3(4):24–33. Режим доступа: https://www.emjreviews.com/respiratory/symposium/type-2-inflammation-and-the-evolving-profile-of-uncontrolled-persistent-asthma/.; Dyneva M., Kurbacheva O., Shilovskiy I., Kovchina V., Savlevich E., Gaysina A. et al. Аnalysis of the expression of th- 1, th- 2, th- 17 cytokines in patients with allergic and non- allergic bronchial asthma associated with chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, Supplement. 2019;74(S106):PD0361. Available at: https://elibrary.ru/item.asp?id=39236801.; Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–420. https://doi.org/10.1007/s11882-013-0373-9.; Murdoch J.R., Lloyd C.M. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39. https://doi.org/10.1016/j.mrfmmm.2009.09.005.; Fahy J.V. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. https://doi.org/10.1038/nri3786.; Vatrella A., Fabozzi I., Calabrese C., Maselli R., Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–130. https://doi.org/10.2147/JAA.S52387.; Slager R.E., Otulana B.A., Hawkins G.A., Yen Y.P., Peters S.P., Wenzel S.E. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol. 2012;130(2):516–522. https://doi.org/10.1016/j.jaci.2012.03.030.; Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258–2261. https://doi.org/10.1126/science.282.5397.2258.; Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia Amirhosseini P., Cook R.M. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130(1):93–100. https://doi.org/10.1046/j.1365-2249.2002.01973.x.; Wenzel S., Wilbraham D., Fuller R., Getz E.B., Longphre M. Effect of an interleu kin-4 variant on late phase asthmatic response to allergen challenge in asth matic patients: results of two Ohase 2a studies. Lancet. 2007;370(9596): 1422–1431. https://doi.org/10.1016/S0140-6736(07)61600-6.; Hanania N.A., Korenblat P., Chapman K.R., Bateman E.D., Kopecky P., Paggiaro P. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, Phase 3, ran domised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–796. https://doi.org/10.1016/S2213-2600(16)30265-X.; Panettieri R.A.Jr., Sjobring U., Peterffy A., Wessman P., Bowen K., Piper E. et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, Phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511–525. https://doi.org/10.1016/S2213-2600(18)30184-X.; Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M. et al. Consensus-based European guidelines for treatment of atopic ecze ma (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Sidbury R., Kodama S. Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648–652. https://doi.org/10.1016/j.clindermatol.2018.05.008.; Wollenberg A., Oranje A., Deleuran M., Simon D., Szalai Z., Kunz B. et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747. https://doi.org/10.1111/jdv.13599.; Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(1 Suppl.):34–40. https://doi.org/10.1159/000370226.; Diamant T., Simpson E.L., Deleuran M., Kataoka Y., Chen Z., Gadkari A et al. Efficacy and safety of dupilumab monotherapy in adults with moderate to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. https://doi.org/10.1016/j.jdermsci.2019.02.002.; Blauvelt A., de Bruin-Weller M., Gooderham M., Cather J.C., Weisman J., Pariser D. et al. Long-term management of moderate-to-severe atopic der matitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1.; Paller A.S., Bansal A., Simpson E.L., Boguniewicz M., Blauvelt A., Siegfried E.C. et al. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119–131. https://doi.org/10.1007/s40257-019-00478-y.; Курбачева О.М., Дынева М.Е., Шиловский И.П., Савлевич Е.Л., Ковчина В.И., Никольский А.А. и др. Особенности молекулярных механизмов патогенеза бронхиальной астмы в сочетании с полипозным риносинуситом. Пульмоно логия. 2021;31(1):7–19. https://doi.org/10.18093/0869-0189-2021-31-1-7-19.; Камалтынова Е.М., Деев И.А., Белоногова Е.Г. Сравнительная эпидемио логическая характеристика бронхиальной астмы по данным программы «Международное исследование астмы и аллергии у детей» (International Study of Asthma and Allergy in Childhood). Бюллетень Сибирской Медицины. 2009;8(4):92–97. Режим доступа: https://www.elibrary.ru/item.asp?id=12966144.; Ненашева Н.М. Значение биомаркеров в диагностике и терапии бронхиальной астмы. Практическая пульмонология. 2017;(4):3–9. Режим доступа: https://www.elibrary.ru/item.asp?id=32734820.; Ненашева Н.М. Фенотипы бронхиальной астмы и выбор терапии. Практическая пульмонология. 2014;(2):2–11. Режим доступа: https://www.elibrary.ru/item.asp?id=23102918.; Busse W.W., Maspero J.F., Rabe K.F., Papi A., Wenzel S.E., Ford L.B. et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018;35(5):737–748. https://doi.org/10.1007/s12325-018-0702-4.; Rabe K.F., Nair P., Brusselle G., Maspero J.F., Castro M., Sher L. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. https://doi.org/10.1056/NEJMoa1804093.; Wenzel S., Castro M., Corren J., Maspero J., Wang L., Zhang B. et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. https://doi.org/10.1016/S0140-6736(16)30307-5.; Tozawa H., Kanki Y., Suehiro J., Tsutsumi S., Kohro T., Wada Y. et al. Genome wide approaches reveal functional interleukin-4-inducible STAT6 binding to the vascular cell adhesion molecule 1 promoter. Mol Cell Biol. 2011;31(11):2196–2209. https://doi.org/10.1128/MCB.01430-10.; Barthel S.R., Johansson M.W., McNamee D.M., Mosher D.F. Roles of integ rin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol. 2008;83(1):1–12. https://doi.org/10.1189/jlb.0607344.; Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77(10):1115–1121. https://doi.org/10.1007/s40265-017-0768-3.; Dyneva M., Kurbacheva O., Shilovskiy I., Savlevich E., Sokolova A., Kovchina V. et al. Characteristic of systemic and local inflammation in nasal polyps comorbid with asthma. Special Issue: Abstracts from the European Academy of Allergy and Clinical Immunology Digital Congress, 06–08 June 2020. 2020;75(S109):1034. https://doi.org/10.1111/all.14508.; Павлова К.С., Дынева М.Е., Курбачева О.М. НПВП-индуцированные респираторные заболевания: эпидемиология, патогенез, клиническая картина и тактика ведения пациентов. Российский аллергологический журнал. 2020;17(3):15–33. Режим доступа: https://www.elibrary.ru/item.asp?id=44167254.; Bachert C., Han J.K., Desrosiers M., Hellings P.W., Amin N., Lee S.E. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusi tis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. https://doi.org/10.1016/S0140-6736(19)31881-1.; Morjaria J.B., Proiti M., Polosa R. Stratified medicine in selecting biologics for the treatment of severe asthma. Curr Opin Allergy Clin Immunol. 2011;11(1):58–63. https://doi.org/10.1097/ACI.0b013e3283423245.; Parulekar A.D., Diamantb Z., Hanania N.A. Role of biologics targeting type 2 airway inflammation in asthma: What have we learned so far? Curr Opin Pulm Med. 2017;23(1):3–11. https://doi.org/10.1097/MCP.0000000000000343.; Zeidler C., Yosipovitch G., Ständer S. Prurigo nodularis and its manage ment. Dermatol Clin. 2018;36(3):189–197. https://doi.org/10.1016/j.det.2018.02.003.; Schuhknecht B., Marziniak M., Wissel A., Phan N.Q., Pappai D., Dangelmaier J. et al. Reduced intraepidermal nerve fibre density in lesional and nonlesion al prurigo nodularis skin as a potential sign of subclinical cutaneous neu ropathy. Br J Dermatol. 2011;165(1):85–91. https://doi.org/10.1111/j.1365-2133.2011.10306.x.; Ständer S., Kwon P., Hirman J., Perlman A.J., Weisshaar E., Metz M. et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Amer Acad Dermatol. 2019;80(5):1395–402. https://doi.org/10.1016/j.jaad.2019.01.052.; Qureshi A.A., Abate L.E., Yosipovitch G., Friedman A.J. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019;80(3):756–764. https://doi.org/10.1016/j.jaad.2018.09.020.; Cevikbas F., Wang X., Akiyama T., Kempkes C., Savinko T., Antal A. et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–460. https://doi.org/10.1016/j.jaci.2013.10.048.; Fukushi S., Yamasaki K., Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990–996. https://doi.org/10.1111/j.1365-2133.2011.10498.x.; Goenka S., Kaplan M.H. Transcriptional regulation by STAT6. Immunol Res. 2011;50(1):87–96. https://doi.org/10.1007/s12026-011-8205-2.; Romano C. Safety and Effectiveness of Dupilumab in Prurigo Nodularis. J Investig Allergol Clin Immunol. 2021;31(2):162–163. https://doi.org/10.18176/jiaci.0550.; O’Shea K.M., Aceves S.S., Dellon E.S., Gupta S.K., Spergel J.M., Furuta G.T., Rothenberg M.E. et al. Pathophysiology of eosinophilic esophagitis. Gastro enterology. 2018;154(2):333–345. https://doi.org/10.1053/j.gastro.2017.06.065.; Rothenberg M.E. Molecular, genetic, and cellular bases for treating eosin ophilic esophagitis. Gastroenterology. 2015;148(6):1143–1157. https://doi.org/10.1053/j.gastro.2015.02.002.; Hirano I., Aceves S.S. Clinical implications and pathogenesis of esophage al remodeling in eosinophilic esophagitis. Gastroenterol Clin North Am. 2014;43(2):297–316. https://doi.org/10.1016/j.gtc.2014.02.015.; Schoepfer A.M., Safroneeva E., Bussmann C., Kuchen T., Portmann S., Simon H.U. et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–1236.e1–2. https://doi.org/10.1053/j.gastro.2013.08.015.; Dellon E.S., Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–322.e3. https://doi.org/10.1053/j.gastro.2017.06.067.; Nicodème F., Hirano I., Chen J., Robinson K., Lin Z., Xiao Y. et al. Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2013;11(9):1101–1107.e1 . https://doi.org/10.1016/j.cgh.2013.03.020.; Arias Á, Pérez-Martínez I., Tenías J.M., Lucendo A.J. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic eosophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3–15. https://doi.org/10.1111/apt.13441.; Rothenberg M.E., Wen T., Greenberg A., Alpan O., Enav B., Hirano I. et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500–507. https://doi.org/10.1016/j.jaci.2014.07.049.; Hirano I., Dellon E.S., Hamilton J.D., Collins M.H., Peterson K., Chehade M. et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults with 3https://doi.org/10.1053/j.gastro.2019.09.042.; Jederlinic P.J., Sicilian L., Gaensler E.A. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore). 1988;67(3):154–162. https://doi.org/10.1097/00005792-198805000-00002.; Marchand E., Reynaud‐Gaubert M., Lauque D., Durieu J., Tonnel A.B., Cordier J.F. Idiopathic chronic eosinophilic pneumonia. A clinical and follow‐up study of 62 cases. The groupe dtudes et de recherche sur les maladies “orphelines” pulmonaires (germ“o”p). Medicine (Baltimore). 1998;77(5):299–312. https://doi.org/10.1097/00005792-199809000-00001.; Fowler С., Hoover W. Dupilumab for chronic eosinophilic pneumonia. Pediatr Pulmonol. 2020;55(12):3229–3230. https://doi.org/10.1002/ppul.25096.
-
14Academic Journal
Συγγραφείς: Baranov, A.A., Namazova-Baranova, L.S., Alexeeva, A.A., Ambarchian, E.T., Aslamazyan, L.K., Astafieva, N.G., Balykova, L.A., Belyaeva, I.A., Bulgakova, V.A., Vakhlova, I.V., Vashakmadze, N.D., Vishneva, E.A., Stasii, E.D., Стасий, Е., Noi, A.
Πηγή: Pediatricheskaya Farmakologiya 35-47
Θεματικοί όροι: Amino acid formula, children, eosinophilic esophagitis, gastroesophageal reflux disease, inflammatory bowel disease, эозинофильный эзофагит, гастроэзофагеальная рефлюксная болезнь, воспалительные заболевания кишечника, аминокислотная смесь, дети
Περιγραφή αρχείου: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/214104; urn:issn:17275776
-
15Academic Journal
Συγγραφείς: Macharadze D.Sh., Larkova I.A., Revjakina V.A., Peshkin V.I., Sadikov I.S.
Πηγή: Аллергология и иммунология в педиатрии
Θεματικοί όροι: clinical case, eosinophilic esophagitis, diagnosis, children, treatment, клинический случай, эозинофильный эзофагит, диагностика, дети, лечение
Διαθεσιμότητα: https://openrepository.ru/article?id=248048
-
16Academic Journal
Συγγραφείς: Yu. V. Yevsyutina, V. T. Ivashkin
Πηγή: Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 3, Pp 11-16 (2016)
Θεματικοί όροι: пищевод баррета, эзофагит, аденокарцинома пищевода, микробиом, эозинофильный эзофагит, пробиотики, RC799-869, Diseases of the digestive system. Gastroenterology, 3. Good health
-
17Academic Journal
Συγγραφείς: Macharadze D.Sh., Larkova I.A., Revjakina V.A., Peshkin V.I., Sadikov I.S.
Πηγή: Аллергология и иммунология в педиатрии
Θεματικοί όροι: eosinophilic esophagitis, clinical case, children, treatment, diagnosis, эозинофильный эзофагит, диагностика, дети, лечение, клинический случай
Σύνδεσμος πρόσβασης: https://openrepository.ru/article?id=248048
-
18
-
19Academic Journal
Συγγραφείς: Gribiniuc, A.I., Грибинюк, А.И., Lupaşco, I.A., Лупашко, Ю.А., Harea, G.G., Berezovscaia, E.S., Berezovskaia, E.S., Березовская, Е.C., Lupaşco, D.F.
Πηγή: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţele vieţii 337 (1) 27-35
Θεματικοί όροι: esofagita eozinofilică, alergie alimentară, dieta alimentară de eliminare, eosinophilic esophagitis, food allergy, elimination food diet, эозинофильный эзофагит, пищевая аллергия, элиминационная пищевая диета
Περιγραφή αρχείου: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/80650; urn:issn:1857064X
Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/80650
-
20Academic Journal
Συγγραφείς: E. Yu. Plotnikova, L. G. Vologzhanina, O. A. Igumnova, T. O. Kolmogorova, Е. Ю. Плотникова, Л. Г. Вологжанина, О. А. Игумнова, Т. О. Колмогорова
Πηγή: Meditsinskiy sovet = Medical Council; № 20 (2017); 124-130 ; Медицинский Совет; № 20 (2017); 124-130 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-20
Θεματικοί όροι: рабепразол, reflux esophagitis, eosinophilic esophagitis, daily pH-metry, rabeprazole, рефлюкс-эзофагит, эозинофильный эзофагит, суточная рН-метрия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2241/2225; Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. The clinical features and predisposing factors of asymptomatic erosive esophagitis. Dig Dis Sci, 2016 Dec, 61(12): 3522-9.; Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol, 2004 Oct, 14(4): 280-6.; Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol, 2009 Dec, 7(12): 1305-13.; Ивашкин В.Т., Баранская Е.К., Трухманов А.С., Кайбышева В.О. Эозинофильный эзофагит. Учебное пособие для врачей. М.: АИСПИ РАН, 2013. 80 с.; Kliemann DA, Pasqualotto AC, Falavigna M, Giaretta T, Severo LC. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop Sao Paulo, 2008 Sep-Oct, 50(5): 261-3.; Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol, 2003, 98(3): S2–S7.; Wilheim AB, Miranda-Filho Dde B, Nogueira RA, Rêgo RS, Lima Kde M, Pereira LM. The resistance to fluconazole in patients with esophageal candidiasis. Arq Gastroenterol, 2009 Jan-Mar, 46(1): 32-7.; Голочевская В.C. Пищеводные боли: умеем ли мы их узнавать? Росс. журн. гастроэнтерол., гепатол., колопроктол., 2001, 16(3): 43–46.; Borowitz SM. Diagnosis: herpes simplex eso phagitis. Clin Pediatr (Phila), 2007 Jul, 46(6): 557-9.; Amaro R, Poniecka AW, Goldberg RI. Herpes esophagitis. Gastrointest Endosc, 2000 Jan, 51(1): 68.; Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep, 2008 Aug, 10(4): 409-16.; Villanueva JL, Torre-Cisneros J, Jurado R, Villar A, Montero M, López F, et al. Leishmania esophagitis in an AIDS patient: an unusual form of visceral leishmaniasis. Am J Gastroenterol, 1994 Feb, 89(2): 273-5.; Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am. J. Gastroenterol. 2003, 98(3): 31–39.; Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol, 2008 Jul, 24(4): 496-501.; Schwartz DA, Pardi DS, Murray AJ. Use of montelukast as steroid sparing agent for recurrent eosinophilic gastroenteritis. Dig. Dis. Sci., 2001, 46: 1787–1790.; Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 2001, 338: 719–726.; Пампура А.Н., Хавкин А.И. Классификация и клинические проявления пищевой аллергии. РМЖ, 2003, 11(20): 1126–1130.; Гусева Н.Г. Висцеральные проявления системной склеродермии. Вестн. РАМН, 2002, 12: 21–25.; Suzuki J, Kawasaki Y, Nozawa R, et al. Oral disodium cromoglycate and ketotifen for a patient with eosinophilic gastroenteritis, food allergy and protein-losing enteropathy. Asian Pac. J. Allergy Immunol, 2003, 21: 193–197.; Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig. Dis., 2004, 22: 108–114.; Sam JW, Levine MS, Rubesin SE, Laufer I. The «foamy» esophagus: a radiographic sign of Candida esophagitis. AJR Am J Roentgenol, 2000 Apr, 174(4): 999-1002.; Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol, 2013 May, 108(5): 679-92.; Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gastroenterology, 2014 Dec, 147(6): 1238-54.; Титгат Г. Эндоскопическое исследование при ГЭРБ. Экспериментальная и клиническая гастро энтерология. Специальный выпуск, 2004, 5: 29–31.; Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H, Ikeuchi S. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. Intern Med, 2017 May 15, 56(10): 1131–1139.; Tytgat GN, Mccoll K, Tack J et al. New algorithm for the treatment of gastro-esophageal reflux diseaseю. Aliment Pharmacol Ther, 2008, 27(3): 249-256.; Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г. Клиническая эффективность рабепразола. Медицинский алфавит, 2017, 9(306): 40-46.; Robinson M, Cheung E, Murthy A, Jokubaitis L. Rabeprazole efficacy in erosive GERD: subgroup analyses from the future of acid suppression therapy (F.A.S.T.) trial. Am J Gastroenterol, 2001, 96(1): S33–S34.; Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev. Gastroenterology & Hepatology, 2012, 6(4): 423-435.